Interventions for the treatment of decreased bone mineral density associated with HIV infection

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2007, Pages

  Lin, D ^b   Rieder, Michael J ^a  

^a CHILDREN S HOSPITAL OF WESTERN ONTARIO   (Canada)

^b NONE

Author keywords

Alendronate therapeutic use ; Bone density conservation agents *therapeutic use ; Bone density *drug effects ; Bone diseases, metabolic *drug therapy ; Calcium, dietary therapeutic use ; HIV infections *complications

Indexed keywords

ALENDRONIC ACID; ANTIRETROVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ETIDRONIC ACID; PLACEBO; RALOXIFENE; RISEDRONIC ACID; TESTOSTERONE ENANTATE; VITAMIN; ZOLEDRONIC ACID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BONE DENSITY; BONE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET THERAPY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG WITHDRAWAL; EXERCISE TEST; FRACTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 44949223486     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005645.pub2     Document Type: Review

References (23)

1. Fairfield 2001 {published data only} Fairfield WP, Finkelstein JS, Klibanski A, Grinspoon SK. Osteopenia in Eugonadal Men with Acquired Immune Deficiency Syndrome Wasting Syndrome. The Journal of Clinical Endocrinology & Metabolism 2001;86(5):2020-26.
2. Guaraldi 2004 {published and unpublished data} Guaraldi G, Orlando G, Madeddu G, Vescini F, Ventura P, Campostrini S, Mura MS, Parise N, Caudarella R, Esposito R. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clinical Trials 2004;5(5):269-77.
3. Mondy 2005 {published and unpublished data} Mondy K, Powderly WG, Claxton SA, Yarasheski KH, Royal M, Stoneman JS, Hoffmann ME, Tebas P. Alendronate, Vitamin D, and Calcium for the Treatment of Osteopenia/Osteoporosis Associated with HIV Infection. Journal of Acquired Immune Deficiency Syndromes 2005;38:426-431.
4. Negredo 2005 {published data only} Negredo E, Martinez-Lopez E, Paredes R, Rosales J, Perez-Alvarez N, Holgado S, Gel S, del Rio L, Tena X, Rey-Joly C, Clotet B. Negredo E, Martinez-Lopez E, Paredes R, Rosales J, Perez-Alvarez N, Holgado S, Gel S, del Rio L, Tena X, Rey-Joly C, Clotet B. Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS 2005;19:343-5.
5. Grinspoon 2006a Androgen Effects in HIV-Infected Women. Ongoing study November 1, 2004.
6. Grinspoon 2006b Physiologic Growth Hormone Effects in HIV Lipodstrophy. Ongoing study January 4, 2005.
7. Huang 2006 Bisphosphonate Therapy for HIV Infected Adults With Decreased Bone Mineral Density. Ongoing study February 4, 2005.
8. McComsey 2006 The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients. Ongoing study May 22, 2003.
9. Rozenberg 2006 Efficacy of Alendronate Versus Placebo in the Treatment of HIV-Associated Osteoporosis. Ongoing study July 11, 2005.
10. van der Ven 2006 The Prevalence of Vitamin D Deficiency and Effects of Vitamin D Supplementation in HIV-1 Infected Patients. Ongoing study March 22, 2006.
11. Amiel 2004 Amiel C, Ostertag A, Slama L, Baudoin C, N'Guyen T, Lajeunie E, Neit-Ngeilh L, Rozenbaum W, De Vernejoul MC. BMD is reduced in HIV-infected men irrespective of treatment. Journal of bone and mineral research 2003;19:402-9.
12. Brown 2004 Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, Timpone J. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. Journal of clinical endocrinology and metabolism 2004;89:1200-6.
13. Bruera 2003 Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003;17:1917-23.
14. Fernandez 2003 Fernandez-Rivera J, Garcia R, Lozano F, Macias J, Garcia-Garcia JA, Mira JA, Corzo JE, Gomez-Mateos J, Rueda A, Sanchez-Burson J, Pineda JA. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials 2003;4:337-46.
15. Huang 2001 Huang JS, Rietschel P, Hadigan CM, Rosenthal DI, Grinspoon S. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS 2001;15:975- 82.
16. Kanis 1994 Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. Journal of bone and mineral research 1994;8:1137-1141.
17. Kanis 2005 Assessment of fracture risk. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N. Osteoporos International 2005;16:581.
18. Landonio 2004 Landonio S, Quirino T, Bonfanti P, Gabris A, Boccassini L, Gulisano C, Vulpio L, Ricci E, Carrabba M, Vigevani GM. Osteopenia and osteoporosis in HIV+ patients, untreated or receiving HAART. Biomedicine & pharmacotherapy 2004;58:505-8.
19. McComsey 2004 McComsey GA, Huang JS, Woolley IJ, Young B, Sax PE, Gerber M, Swindells S, Bonilla H, Gopalakrishnan G. Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management. Journal of the International Association of Physicians in AIDS Care 2004;3:86.
20. Mondy 2003 Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, Hoffmann M, Tebas P. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clinical infectious diseases 2003;36:482-90.
21. Moore 2001 Moore AL, Vashisht A, Sabin CA, Mocroft A, Madge S, Phillips AN, Studd JW, Johnson MA. Reduced bone mineral density in HIV-positive individuals. AIDS 2001;15:1731-3.
22. NIH 1993 National Institute of Health. NIH Consensus Development Conference: Diagnosis, prophylaxis, and treatment of osteoporosis. American journal of medicine 1993 650 193; 94:646- 650;94:646-650.
23. Tebas 2000 Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, Yarasheski KE. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000;14:F63-7.